1cP-AL-LAD

Chemical compound vanc 6 1cP-AL-LAD.svg skin-invert-image 175px 1cP-AL-LAD 3D.png bg-transparent 250px Oral Serotonergic psychedelic; Hallucinogen 7–10 hours 3028950-72-0 162368406 HH7F72QLZ3 (6aR,9R)-4-(cyclopropanecarbonyl)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide 26 31 3 2 CCN(CC)C(=O)[C@@H]1C=C2[C@@H](Cc3cn(C(=O)C4CC4)c4cccc2c34)N(C1)CC=C 1S/C26H31N3O2/c1-4-12-28-15-19(25(30)27(5-2)6-3)13-21-20-8-7-9-22-24(20)18(14-23(21)28)16-29(22)26(31)17-10-11-17/h4,7-9,13,16-17,19,23H,1,5-6,10-12,14-15H2,2-3H3/t19-,23-/m1/s1 VSABTUDYQCMWKE-AUSIDOKSSA-N 1cP-AL-LAD is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Stratford A, Auwärter V, Chapman SJ, Halberstadt AL, Brandt SD Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities Drug Test Anal 15 3 277–291 March 2023 36321499 10.1002/dta.3397 free 1cP-AL-LAD АИПСИН https://aipsin.com/newsubstance/595/ ru 1 January 20261cP-AL-LAD АИПСИН https://aipsin.com/newsubstance/714/ ru 1 January 2026 It is thought to act as prodrug of AL-LAD. The drug has been encountered as a novel designer drug. Use and effects AL-LAD#Use and effects The dose of 1cP-AL-LAD ranges from 20 to 350μg orally, with an average dose being 100 to 225μg. Its duration is said to be 7 to 10hours. The drug is said to produce psychedelic effects that are weaker and shorter-lasting than those of LSD. Interactions Psychedelic drug#Interactions Trip killer#Serotonergic psychedelic antidotes Chemistry Analogues Related compounds include 1cP-LSD, 1D-LSD, 1P-AL-LAD, and 1T-AL-LAD, among others. History 1cP-AL-LAD has been sold as a designer drug. It was first identified online in December 2020 and in France in June 2021. Morais J, Evans-Brown M, Gallegos A, Christie R, Jorge R, Planchuelo G, Sedefov R 2022-09-01 New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System https://www.sciencedirect.com/science/article/pii/S2352007822000944 Toxicologie Analytique et Clinique 30th meeting of SFTA- 59th meeting of TIAFT - September 2022 34 3, Supplement S29–S30 10.1016/j.toxac.2022.06.022 2022ToxAC..34S..29M 2352-0078 subscription Society and culture Legal status Canada 1cP-AL-LAD is not a controlled substance in Canada as of 2025.Controlled Drugs and Substances Act Department of Justice Canada https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html 19 January 2026 United States 1cP-AL-LAD is not an explicitly controlled substance in the United States. Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) January 2026 U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division United States https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. See also Substituted lysergamide Lizard Labs References External links 1cP-AL-LAD - Isomer Design 1cP-AL-LAD - PsychonautWiki Category:5-HT2A agonists Category:Cyclopropyl compounds Category:Designer prodrugs Category:Diethylamides Category:Psychedelic lysergamides Category:Serotonin receptor agonists